Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

BACKGROUND AND OBJECTIVE: To avoid insulin-induced hypoglycemia and weight gain, the minimum dose of insulin should be used. In this study, therefore, we examined insulin dose reduction by ipragliflozin add-on therapy in Japanese patients with type 2 diabetes mellitus treated with long-acting basal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihara, Hisamitsu, Yamaguchi, Susumu, Sugitani, Toshifumi, Kosakai, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842350/
https://www.ncbi.nlm.nih.gov/pubmed/31552641
http://dx.doi.org/10.1007/s40261-019-00851-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842350/
https://www.ncbi.nlm.nih.gov/pubmed/31552641
http://dx.doi.org/10.1007/s40261-019-00851-z

Ejemplares similares